Details for Patent: 8,623,920
✉ Email this page to a colleague
Which drugs does patent 8,623,920 protect, and when does it expire?
Patent 8,623,920 protects ZIPSOR and is included in one NDA.
Summary for Patent: 8,623,920
| Title: | Method of treating post-surgical acute pain |
| Abstract: | A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients. |
| Inventor(s): | Kowalski; Mark M. (Winchester, MA), Young; James L. (Valley Park, MO), Moore; Keith A. (Loveland, OH) |
| Assignee: | Depomed, Inc. (Newark, CA) |
| Application Number: | 13/205,033 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 8,623,920
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
